XML 20 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 2,801 $ 2,165
Accounts receivables, net of allowance for credit losses of $91 million and $90 million as of December 31, 2022 and December 31, 2021, respectively 3,696 4,529
Inventories 3,833 3,818
Prepaid expenses 1,162 1,075
Other current assets 549 965
Assets held for sale 10 19
Total current assets 12,051 12,573
Deferred income taxes 1,453 596
Other non-current assets 441 515
Property, plant and equipment, net 5,739 5,982
Operating lease right-of-use assets 419 495
Identifiable intangible assets, net 6,270 7,466
Goodwill [1] 17,633 [2] 20,040
Total assets 44,006 47,666
Current liabilities:    
Short-term debt 2,109 1,426
Sales reserves and allowances 3,750 4,241
Accounts payables 1,887 1,686
Employee-related obligations 566 563
Accrued expenses 2,151 2,208
Other current liabilities 1,005 903
Total current liabilities 11,469 11,027
Long-term liabilities:    
Deferred income taxes 548 784
Other taxes and long-term liabilities 3,847 2,578
Senior notes and loans 19,103 21,617
Operating lease liabilities 349 416
Total long-term liabilities 23,846 25,395
Commitments and contingencies, see note 12
Total liabilities 35,315 36,422
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; December 31, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,217 million shares and 1,209 million shares, respectively 57 57
Additional paid-in capital 27,688 27,561
Accumulated deficit (12,882) (10,529)
Accumulated other comprehensive loss (2,838) (2,683)
Treasury shares as of December 31, 2021 and December 31, 2020: 106 million ordinary shares (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 7,897 10,278
Non-controlling interests 794 966
Total equity 8,691 11,244
Total liabilities and equity $ 44,006 $ 47,666
[1] Accumulated goodwill impairment as of December 31, 2022, December 31, 2021 and December 31, 2020 was approximately $27.6 billion, $25.6 billion and $25.6 billion, respectively.
[2] As of December 31, 2022, “Other” includes $1,293 million goodwill balance related to Teva’s API reporting unit.